Our mission: to redefine the standard of care in hair loss

Hair loss affects women, too. But are their treatment options keeping pace?

Up to 50% of women may experience androgenetic alopecia by age 70. Yet the 2025 Canadian consensus identifies topical minoxidil as the only first-line pharmacological treatment for female pattern hair loss.

Other approaches, including off-label antiandrogen therapies, come with different considerations and an evidence base that still has important gaps.

Swipe through to explore where the research stands and why more evidence matters.

#FemalePatternHairLoss#WomensHealth#HairLoss#AndrogeneticAlopecia#Dermatology

Same molecule, different route, different questions.

A 2025 meta-analysis of six randomized controlled trials involving 1,104 men examined adverse events associated with topical finasteride for androgenetic alopecia.

The analysis found no statistically significant increase in erectile dysfunction or reduced libido compared with placebo. The authors also highlighted an important consideration: compounded topical formulations can vary, making standardization and further study important.

Understanding both the findings and their limitations is essential when evaluating treatment options.

#Finasteride#HairLoss#AndrogeneticAlopecia#DrugSafety#Dermatology

Can combining two treatment mechanisms make a difference?

A 2025 meta-analysis of seven randomized controlled trials involving 396 men with androgenetic alopecia compared topical minoxidil plus finasteride with minoxidil alone. The combination was associated with greater hair density, increased hair diameter, and higher odds of marked improvement in global assessments.

The findings are promising, but the authors rated the certainty of evidence as moderate and called for larger confirmatory trials.

See the key numbers and what the research found.

#CombinationTherapy#HairLoss#AndrogeneticAlopecia#ClinicalEvidence#Dermatology

Men’s health deserves attention all year. Movember helps put it in the spotlight.

From prostate cancer research, mental health and suicide prevention, Movember encourages people to move conversations forward and take action for men’s health, mind, and body.

We believe hair loss deserves a place in that conversation, too and that’s why, this Movember, we’re helping bring awareness to the broader impact of hair loss and the importance of recognizing men’s health in all its forms.

Learn more about the movement and how to get involved at @movember or movember.com.

#Movember#MensHealth#HairLossAwareness#MentalHealthAwareness

Combination therapy is already part of how several chronic diseases are managed. In hypertension, glaucoma, and type 2 diabetes, guidelines describe combining therapies with different mechanisms in situations where one treatment may not be enough or where combination treatment offers practical advantages.

AGA is also a multifactorial condition. That doesn’t mean the same approach should automatically be applied to hair loss, but it does raise an important research question: could complementary mechanisms play a role in future combination strategies for AGA?

References: McCarthy CP, Bruno RM, McEvoy JW, Touyz RM. Eur Heart J Cardiovasc Pharmacother. 2025;11(1):7–9. Pazos M, Traverso CE, Viswanathan A, et al. Br J Ophthalmol. 2025;109(Suppl 1):1–212. American Diabetes Association Professional Practice Committee. Diabetes Care. 2026;49(Suppl 1)–S215.

#CombinationTherapy#AndrogeneticAlopecia#AGA#HairScience#EvidenceBasedMedicine#Dermatology

Androgenetic alopecia is a chronic condition. The treatments we have today are maintenance treatments.

In a long-term trial cited in a 2026 review, improvements achieved with topical minoxidil returned to values comparable to baseline by week 104 after treatment was discontinued (Bhoyrul et al., 2026). The Canadian consensus on androgenetic alopecia describes the disease as chronic, requiring ongoing management (Landells et al., 2025).

For patients, this means every treatment decision is a decision about years, not weeks. Efficacy, tolerability and the daily routine all have to hold up over that horizon.

#HairLoss#AndrogeneticAlopecia#ChronicCondition#Adherence#Dermatology

Androgenetic alopecia is more complex than a single hormone or pathway. Research has identified several biological processes involved in the condition. Understanding how these processes contribute to follicular miniaturization is an important part of understanding AGA itself.

The first step toward better understanding is recognizing that there may be more than one mechanism to study.

Reference: Chen S, Li L, Ding W, Zhu Y, Zhou N. *Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.* Drug Des Devel Ther. 2025;19:7349–7363.

#AndrogeneticAlopecia#AGA#HairScience#HairLossResearch#Dermatology#Pathophysiology

Minoxidil doesn’t work the same way for everyone, and part of the reason may be happening inside the hair follicle. A 2026 review reports that approximately 60% of users may not achieve visible improvement, highlighting an important question in hair-loss research: why do some follicles respond while others don’t?

#Minoxidil#AndrogeneticAlopecia#AGA#HairScience#Pharmacology#DermatologyReference: Dias FR, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B. *Front Pharmacol.* 2026;16:1718208.

Menopause changes more than reproductive hormones. It can also change the environment in which hair follicles grow.

Hair loss around menopause is an important area of women’s health, yet dedicated clinical evidence remains limited.

This World Menopause Day, let’s include hair in the conversation.

Reference: Gupta AK, Economopoulos V, Mann A, Wang T, Mirmirani P. *Menopause and hair loss in women: exploring the hormonal transition.* Maturitas. 2025;198:108378.

#WorldMenopauseDay#FemalePatternHairLoss#WomensHealth#Menopause#HairScience#Dermatology

AGA is common, but its prevalence is easy to underestimate. Up to 50% of men and up to 40% of women are affected. By age 50, half of all men show signs of AGA; by age 70, prevalence reaches up to 80% in men and up to 50% in women, with a marked increase after menopause.

A condition this common deserves continued scientific attention.

Sources: Landells I, et al. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. J Cutan Med Surg. 2025;29(5 Suppl):5S-14S. doi:10.1177/12034754251368849; Bhoyrul B, et al. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia. Front Pharmacol. 2026;16:1718208. doi:10.3389/fphar.2025.1718208

#AndrogeneticAlopecia#AGA#HairLoss#HairScience#Dermatology